CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 109 enrolled
Drug / intervention
Tixel C +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05162261
NCT05162261N/ACompleted
CompareCT.gov

A Randomized, Masked (Evaluator), Controlled, Prospective Study Evaluating the Effectiveness and Safety of the Tixel® Medical Device, Versus LipiFlow® in the Treatment of Meibomian Gland Dysfunction

Novoxel Ltd.·interventional·Posted Dec 17, 2021·Updated Jan 22, 2025

In Brief

A clinical study evaluating Tixel C and LipiFlow for Meibomian Gland Dysfunction and 2 related conditions. Completed, enrolled 109 participants across 5 sites.

Detailed Summary

A Randomized, Masked (Evaluator), Controlled, Prospective Study Evaluating the Effectiveness and Safety of the Tixel® Medical Device, Versus LipiFlow® in the Treatment of Meibomian Gland Dysfunction

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMeibomian Gland Dysfunction, Dry Eye Syndromes, Dry Eye
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedDec 17, 2021
Enrollment StartSep 19, 2022
Primary CompletionApr 26, 2023
Study CompletionSep 28, 2023
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 4.5 years ago

Interventions

Tixel Cdevice

Tixel C by Novoxel®, Israel is a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling tissue coagulation combined with micro ablation with low thermal damage to the surrounding tissue.

LipiFlowdevice

Thermal pulsation (LipiFlow) consists of the localized application of heat and therapeutic pressure on the four eyelids (upper and lower) with the aim of improving drainage of the Meibomian glands.